Corrigendum: Systems pharmacology approach to investigate the mechanism of Kai-Xin-San in Alzheimer’s disease

Frontiers in Pharmacology

Pharmacology

Hanzhong Ke¹  Honghai Hong²  Yumin Xu³  Huilin Li⁴  Qihui Wu⁵  Chuipu Cai⁵  Xinning Liu⁵  Dongli Li⁵  Yanfang Liao⁵  Yunxia Luo⁶  Qi Wang⁷  Jiansong Fang⁷  Shuhuan Fang⁷ 

[1] Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA, United States;Department of Medicine, Harvard Medical School, Boston, MA, United States;Department of Clinical Laboratory, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;Department of Encephalopathy First Affiliated Hospital of Henan University of Chinese Medicine, Zhengzhou, China;Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China;Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China;Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China;Department of Endocrinology, Fourth Clinical Medical College, Guangzhou University of Chinese Medicine, Shenzhen, China;Science and Technology Innovation Center, Guangzhou University of Chinese Medicine, Guangzhou, China;Institute of Clinical Pharmacology, Guangzhou University of Chinese Medicine, Guangzhou, China;

关键词: systems pharmacology;    Kai-Xin-San;    Alzheimer’s disease;    cholinergic system;    neuroinflammation;   

DOI  :  10.3389/fphar.2023.1239060

 received in 2023-08-23, accepted in 2023-09-22,  发布年份 2023

来源: Frontiers

【 授权许可】

Unknown   
Copyright © 2023 Luo, Li, Liao, Cai, Wu, Ke, Liu, Li, Hong, Xu, Wang, Fang and Fang.